MedCity News

BioPharma, Pharma

$10B M&A Deal Pays Off With GSK’s First Lung Cancer Drug Approval

By Frank Vinluan

Health Tech

Headspace Teams Up with 4 Companies for Specialty Care

Headspace announced partnerships with Charlie Health, Cortica, Prosper Health and Equip.

By Marissa Plescia

MedCity Influencers

Hidden in Plain Sight: The Cost Crisis in Women’s Healthcare

Women have to navigate the fragmented system with very little support, coordinating between providers and often interpreting conflicting guidance.

By Chevon Rariy and Kara Ellinger

MedCity Influencers

Wooden mannequin holding a US $100 dollar bill on a defocused stethoscope background.

What Healthcare Organizations Miss When It Comes to Reimbursement Accuracy

At the end of the day, the most important question is a simple one: Do you actually know if you’re being reimbursed correctly?

By Elevsis Delgadillo

Latest Video

Latest News

Opinion

Better Prescribing, Not Less Prescribing, Is What Behavioral Health Needs

The policy conversation needs to shift from just deprescribing alone to building the clinical infrastructure that delivers consistent, high-quality behavioral health care.

By Dr. Caroline Carney

BioPharma, Devices & Diagnostics, Health Tech

Digitally generated image of multi coloured vertical bars. Concept of fintech technology, new banking and investment. Clean design.

You Can Now Bet on Clinical Trials Like Playoff Games, But Health Execs Say It Crosses a Line

Prediction market Kalshi launched betting markets tied to clinical trial results and FDA approvals. Healthcare leaders warn the model could invite insider trading and distort the integrity of the research outcomes it's meant to forecast.

By Katie Adams

Policy

affordable care act marketplaces coverage

New Bill Seeks to Create Public Option on ACA Marketplaces

Rep. Angie Craig introduced a bill to establish a public health insurance option on the ACA marketplaces and permanently extend enhanced premium tax credits.

By Marissa Plescia

BioPharma, Pharma

Agios Pharma Drops Sickle Cell Disease Drug After Phase 2 Data Disappoint

Agios Pharmaceuticals said tebapivat fell short of expectations in a Phase 2 test in sickle cell disease. It’s the latest in a series of disappointing industry developments in sickle cell disease.

By Frank Vinluan

MedCity Influencers

How Diagnostic Precision in Allergy Care Supports Mental Well-Being

Screening for mental health symptoms in patients with significant allergic disease is not overreach

By Gary Falcetano

MedCity Influencers

Why Pharma Companies Should Look To Social Media For Better Patient Insight

Healthcare decision-makers, especially at pharmaceutical companies, must prioritize patient input. Data collected from social media listening is a significant step in the right direction.

By Rohit Marwah

Where Will AI Deployment Benefit Payers the Most?

A five minute survey from MedCity News asks payers what they think of AI and how it is being implemented. Participate today and we will reward you!

By Stephanie Baum

Artificial Intelligence, Hospitals, Health Tech, Providers

Hackers work secretly in secret rooms. Mysterious colored lights Breaking into personal security and various agencies in the world . Wanted Hacker using computer for hacking in the cyber data center .

The Same AI That Helps Patients Is Being Used to Attack Them, Hospital Exec Says

As hospitals increasingly use AI to improve patient care, the same technology is being used by hackers and nation-states to launch faster, more sophisticated attacks. Karen Habercoss, chief information security and privacy officer at the University of Chicago Medicine, explained how her health system is building a governance structure to manage that risk.

By Katie Adams

Health Tech

How Should Clinical AI Be Paid For? 3 Takeaways

A new report from the Peterson Health Technology Institute argues that today's healthcare payment models are ill-suited for clinical AI and could drive up costs.

By Marissa Plescia

Diagnostics, BioPharma, Artificial Intelligence

Expecting Massive Test Growth in Cancer & More, Tempus AI Strikes $1.5B Deal to Buy Personalis

Personalis’s liquid biopsy is part of a growing market for minimal residual disease assays, tests that look for any remaining cancer cells after the initial treatment. Tempus AI has been the commercial partner on this Personalis test since 2023.

By Frank Vinluan

MedCity Influencers

The AI Tension in Healthcare: Patent Strategy, FDA Reality, and HIPAA Constraints

These three legal regimes are pulling in different directions, and the developers that navigate them well will be the ones that plan for all three from the start.

By Robert Botkin, Marci Norton, Tim St. Clair, Olivia Osburn, and Caroline McCracken

MedCity Influencers

For Millions in Rural America, Medicine Is Still Far Away

Rural Health Transformation Program funding gives states broad flexibility and may help address longstanding access gaps.

By Miriam Paramore

Health Tech

Ovarian and Cervical Cancer Awareness. Woman Holding Teal Ribbon on Lower Abdomen, Uterus, Female Reproductive System, Women's Health, PCOS and Gynecology

Women’s Oncology Market Could Reach $110B in 2030, but Gaps Remain

A new PwC report says the women's oncology market could reach $110 billion by 2030, though funding and care gaps remain.

By Marissa Plescia

Pharma, BioPharma

Merck Pill Becomes First Oral Option in Growing Class of Cholesterol-Lowering Drugs

Merck’s Lipfendra is the first FDA-approved pill in the class of cholesterol-lowering drugs called PCSK9 inhibitors. While peptides are typically injected, Lipfendra is a macrocyclic peptide designed for formulation as an oral drug.

By Frank Vinluan

MedCity Influencers

Financial investment management or wealth management. Isometric merchants conducting business activities

Hybrid Financing in Life Sciences: Unlocking Growth Amid Market Challenges

What should life sciences investors and targets focus on for dealmaking success? Here are six actionable steps.

By Kristian A. Werling and Todd Finger